JP2020528910A - オリゴヌクレオチド化合物の調製方法 - Google Patents

オリゴヌクレオチド化合物の調製方法 Download PDF

Info

Publication number
JP2020528910A
JP2020528910A JP2020504133A JP2020504133A JP2020528910A JP 2020528910 A JP2020528910 A JP 2020528910A JP 2020504133 A JP2020504133 A JP 2020504133A JP 2020504133 A JP2020504133 A JP 2020504133A JP 2020528910 A JP2020528910 A JP 2020528910A
Authority
JP
Japan
Prior art keywords
mmol
oligonucleotide
certain embodiments
composition according
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020504133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528910A5 (https=
Inventor
フランク アンソニー
フランク アンソニー
クロップフェル ケビン
クロップフェル ケビン
ジョセフ ジュニア．ギャラガー ドナルド
ジョセフ ジュニア．ギャラガー ドナルド
ジャファルポウル ラレフ
ジャファルポウル ラレフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2020528910A publication Critical patent/JP2020528910A/ja
Publication of JP2020528910A5 publication Critical patent/JP2020528910A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020504133A 2017-07-28 2018-07-26 オリゴヌクレオチド化合物の調製方法 Pending JP2020528910A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538504P 2017-07-28 2017-07-28
US62/538,504 2017-07-28
PCT/US2018/043867 WO2019023439A1 (en) 2017-07-28 2018-07-26 PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDE COMPOUNDS

Publications (2)

Publication Number Publication Date
JP2020528910A true JP2020528910A (ja) 2020-10-01
JP2020528910A5 JP2020528910A5 (https=) 2021-09-09

Family

ID=65041406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020504133A Pending JP2020528910A (ja) 2017-07-28 2018-07-26 オリゴヌクレオチド化合物の調製方法

Country Status (6)

Country Link
US (1) US20200392491A1 (https=)
EP (1) EP3658155A4 (https=)
JP (1) JP2020528910A (https=)
KR (1) KR20200042902A (https=)
CN (1) CN111148519A (https=)
WO (1) WO2019023439A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505598A (ja) 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法
CN113474633A (zh) * 2019-02-26 2021-10-01 罗氏创新中心哥本哈根有限公司 寡核苷酸配制方法
AU2020309307B2 (en) * 2019-07-09 2023-03-30 F. Hoffmann-La Roche Ag Process for the deprotection of oligonucleotides
CN110468171B (zh) * 2019-09-20 2021-10-29 凯莱英医药集团（天津）股份有限公司 核酸的合成方法
WO2021168306A1 (en) * 2020-02-21 2021-08-26 Biogen Ma Inc. Methods of preparing oligonucleotide compositions using ultrafiltration / diafiltration
WO2024138152A1 (en) * 2022-12-23 2024-06-27 Asahi Kasei Bioprocess America, Inc. System for performing cleavage, deprotection, ultrafiltration, and diafiltration operations
CN117143165B (zh) * 2023-08-30 2026-02-03 上海奥锐特生物科技有限公司 一种寡核苷酸的纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050789A2 (en) * 2005-10-25 2007-05-03 Nëdken Corporation Glycosyl-oligonucleotide conjugates and methods
WO2014120861A2 (en) * 2013-01-31 2014-08-07 Isis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified coupling protocols
AU2015257589A1 (en) * 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
WO2015011694A2 (en) * 2014-10-17 2015-01-29 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
EP3355896A2 (en) * 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Also Published As

Publication number Publication date
US20200392491A1 (en) 2020-12-17
KR20200042902A (ko) 2020-04-24
EP3658155A4 (en) 2021-06-30
EP3658155A1 (en) 2020-06-03
CN111148519A (zh) 2020-05-12
WO2019023439A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
JP2020528910A (ja) オリゴヌクレオチド化合物の調製方法
JP7442574B2 (ja) Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP3926840B2 (ja) 遺伝子発現をダウンレギュレートするための２’−置換オリゴヌクレオチドの使用
US20170247695A1 (en) Isotopologues of smad7 antisense oligonucleotides
JP2002510319A (ja) オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
TW201639962A (zh) Ｒｎａ干擾劑
EA008741B1 (ru) Аналоги олигонуклеотидов с-класса с улучшенной иммуностимулирующей эффективностью
JPH08505396A (ja) 酸性ｐＨにおいて安定性を増加するよう修飾されたオリゴヌクレオチド
EP3286203B1 (en) Methods of polynucleotide preparation using multivalent cation salt compositions
US20210269797A1 (en) Methods and compositions for targeting pd-l1
CN118202054A (zh) 一种调节补体C5表达的siRNA、其缀合物和药物组合物及用途
JPH07501314A (ja) ３′−末端封鎖されたオリゴヌクレオチド
KR20140044324A (ko) 페길화된 올리고뉴클레오티드의 제조방법
CN118685411B (zh) 抑制agt基因表达的双链寡核苷酸、其缀合物及用途
CN118202053A (zh) 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途
WO2024169908A1 (zh) 一种调节补体C5表达的siRNA、其缀合物和药物组合物及用途
CN111321159B (zh) 用于免疫调节的嵌合核酸分子及其应用
Chaix et al. 3′-3′-linked oligonucleotides: Synthesis and stability studies
WO2024169907A1 (zh) 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途
TW202604550A (zh) 抑制ａｎｇｐｔｌ３基因表達的核酸分子
AU755786B2 (en) Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO2025240884A1 (en) Patterned modified oligonucleotides
CN121729495A (zh) 靶向pd-l1的双链核糖核酸
HK40109846A (zh) 减少papd5和papd7 mrna的核酸分子用於治疗乙型肝炎感染
CN120456911A (zh) 用于抑制补体组分C3(C3)表达的RNAi剂、其药物组合物及使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200611

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230221